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cost for acute period of MI at hospital was 25,340.00 rubles
($794.36) per patient. There was no signiﬁcant difference
between 3 hospitals. Median total cost for follow-up period in
ﬁrst 6 months after MI was 28,706.63 rubles ($899.89) per
patient for services and drugs mentioned by experts. Median cost
for second 6 months was 11,626.71 rubles ($364.47) per patient;
each 6 months after it required 10,722.73 rubles ($336.14).
CONCLUSION: Costs are relatively low because of rare use of
expensive technologies: only 15% of patients received throm-
bolytical therapy; no coronary artery bypass surgery or stent
implantation were used.
PCV39
MODELING THE ECONOMIC CONSEQUENCES OF
IMPLANTING DUAL CHAMBER VS. SINGLE CHAMBER
PACEMAKERS IN THE UK
Caro JJ,Ward AJ
Caro Research Institute, Concord, MA, USA
OBJECTIVES: To estimate the long-term economic and health
impact of managing bradycardia due to sinoatrial node disease
or atrioventricular block with a dual chamber (DDD or DDDR)
vs. single-chamber ventricular pacemaker (VVI or VVIR).
METHODS: A discrete event simulation of 2 identical cohorts
of 1000 patients for 5 years after implantation tracks develop-
ment of post-operative complications, severe pacemaker syn-
drome leading to replacement, atrial ﬁbrillation (which may
become chronic and require anticoagulants), and stroke. Life
expectancy is assumed the same with either device. Risk func-
tions were developed for each device based on two long-term
randomized trials (Canadian Trial of Physiological Pacing,
CTOPP and Mode Selection Trial in Sinus-Node Dysfunction,
MOST). Sensitivity analyses were completed for key input para-
meters. Direct medical costs to the NHS are reported in 2003
British Pounds Sterling (GBP). Beneﬁts were discounted at 1.5%,
and costs 6%. RESULTS: Overall, 29.1% in each cohort died
within 5 years of the implant. Post-operative complications
requiring reoperation increased from 6.4% for VVI(R) to 7.7%
with DDD(R), atrial ﬁbrillation dropped from 22% to 18%;
severe pacemaker symptoms developed in 16.8% with VVI(R)
leading to a wish to switch to DDD(R). Total costs over 5 years
were about 4300 GBP per patient in either cohort. Based on 
100 replications, additional health beneﬁts from DDD(R) are
achieved with a mean net cost of 43 GBP per patient, and 
0.09 QALY gained: a mean cost-effectiveness ratio of 477 GBP
per QALY. In 26% of the replications, however, dual chamber
dominates single chamber. CONCLUSIONS: Whilst implanting
the DDD(R) increases the cost of the initial implantation, this is
predicted to be largely offset by a reduction in long-term 
complications when compared with VVI(R).
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OBJECTIVE: To calculate costs for patients with ischemic stroke
(IS) in common medical practice in Russian Federation.
METHODS. Data on resource use for hospital treatment of
patients with IS were extracted from 70 medical charts at 2 hos-
pitals at Moscow. Data on resource use for out-patient follow-
up for patients after acute myocardial infarction were identiﬁed
according to experts’ opinion. Six experts ﬁlled in the question-
naire for identifying typical follow-up strategy for 1.5 years after
MI. Direct medical costs were calculated on the basis of price-
lists for medical services and median prices for drugs given in a
wholesale pharmaceutical informational bulletin. RESULTS:
Median cost for acute period of IS at hospital was 25,187.00
rubles ($789.56) per patient. There was some difference in costs
between 2 hospitals, but no statistical signiﬁcance was found.
Computer tomography was performed only in 38% patients
(mostly at one hospital). Median total cost for follow-up period
in ﬁrst 6 months after IS was 42,644.50 rubles ($1336.82) per
patient for services and drugs mentioned by experts. Median 
cost for second 6 months was 13,561.08 rubles ($425.11) per
patient; each 6 months after it required 9996.69 rubles
($313.38). CONCLUSIONS: According to experts’ opinion
carotid endarterectomy is performed in no more than 10%
patients after IS.
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OBJECTIVES: Pharmaceutical treatment of hypercholes-
terolemia is recommended in individuals with a LDL-cholesterol
level of ≥190mg/dl and 130–189mg/dl plus two other coronary
heart disease risk factors or a coronary heart disease risk >20%
in 10 years. The objective of this study was to assess the 
cost-effectiveness of pharmaceutical treatments of hypercholes-
terolemia in Catalonia, Spain. METHODS: Treatments evalu-
ated included 20, 40, and 80mg/day of lovastatin and
ﬂuvastatin, 10, 20, and 40mg/day of pravastatin, simvastatin
and atorvastatin, 12 and 24g/day of cholestyramine, and 
1.2g/day of gemﬁbrozil. The cost-effectiveness was evaluated
comparing annual treatment costs and the percentage of LDL-
cholesterol reduction. Treatment costs included medication,
medical visits control measures, and treatment of secondary
adverse effects. Wholesale prices in 2002 were used to estimate
medication costs. A metanalysis was carried out to estimate
effectiveness of different treatments, including all published ran-
domized, double blind clinical trials referred on Medline from
1991 to 2002. RESULTS: The annual cost of medication ranged
from 332.98€ for 20mg/day lovastatin to 1105.17€ for 
40mg/day atorvastatin. The percentage of LDL-cholesterol
reduction ranged from 10% for 12g/day cholestyramine to 49%
for 80mg/day atorvastatin. The average cost-effectiveness ratios
in terms of € per one per cent of LDL-cholesterol reduced were
11.22€–22.55€ for atorvastatin, 12.00–21.96€ for simvastatin,
13.87–21.64€ for lovastatin, 15.24–24.69€ for ﬂuvastatin,
20.96–41.77€ for pravastatin, 32.61€ for gemﬁbrozil, and
35.21–45.55€ for cholestyramine. The incremental cost-
effectiveness analysis showed that the more efﬁcient cholesterol-
lowering therapies were 10mg/day atorvastatin, 10mg/day 
simvastatin, 20mg/day lovastatin, 20mg/day ﬂuvastatin, and 20,
40 and 80mg/day atorvastatin. CONCLUSIONS: Efﬁcient statin
therapies detected in this study should be the ﬁrst election cho-
lesterol-lowering drugs used in patients with hypercholes-
terolemia in Catalonia.
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OBJECTIVE: Research has shown that most smokers start
before the age of 18 and after that age the probability to start-
ing smoking decreases steadily. Furthermore, smokers who start
earlier in life are less likely to quit and reducing or delaying 
initiation could have a large impact on public health. In 2002,
